Suffolk Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | $367K | Sell |
4,335
-1,199
| -22% | -$102K | 0.07% | 89 |
|
|
2018
Q3 | $948K | Sell |
5,534
-1,367
| -20% | -$234K | 0.13% | 66 |
|
|
2018
Q2 | $892K | Sell |
6,901
-575
| -8% | -$74.3K | 0.13% | 75 |
|
|
2018
Q1 | $770K | Sell |
7,476
-5,771
| -44% | -$594K | 0.11% | 101 |
|
|
2017
Q4 | $1.13M | Buy |
13,247
+3,823
| +41% | +$327K | 0.15% | 58 |
|
|
2017
Q3 | $800K | Sell |
9,424
-12,500
| -57% | -$1.06M | 0.11% | 107 |
|
|
2017
Q2 | $1.66M | Buy |
21,924
+3,044
| +16% | +$230K | 0.22% | 78 |
|
|
2017
Q1 | $1.25M | Sell |
18,880
-1,856
| -9% | -$123K | 0.17% | 111 |
|
|
2016
Q4 | $1.31M | Sell |
20,736
-4,202
| -17% | -$266K | 0.18% | 112 |
|
|
2016
Q3 | $1.59M | Sell |
24,938
-7,855
| -24% | -$500K | 0.22% | 82 |
|
|
2016
Q2 | $2.44M | Buy |
32,793
+9,498
| +41% | +$707K | 0.31% | 94 |
|
|
2016
Q1 | $1.56M | Sell |
23,295
-11,262
| -33% | -$752K | 0.21% | 129 |
|
|
2015
Q4 | $2.34M | Sell |
34,557
-10,713
| -24% | -$724K | 0.3% | 106 |
|
|
2015
Q3 | $2.42M | Buy |
45,270
+5,886
| +15% | +$315K | 0.32% | 93 |
|
|
2015
Q2 | $2.48M | Sell |
39,384
-28,713
| -42% | -$1.81M | 0.29% | 110 |
|
|
2015
Q1 | $3.28M | Sell |
68,097
-17,922
| -21% | -$862K | 0.38% | 71 |
|
|
2014
Q4 | $2.86M | Buy |
86,019
+32,639
| +61% | +$1.08M | 0.35% | 94 |
|
|
2014
Q3 | $1.57M | Sell |
53,380
-16,030
| -23% | -$470K | 0.19% | 127 |
|
|
2014
Q2 | $2.7M | Buy |
69,410
+25,327
| +57% | +$984K | 0.33% | 100 |
|
|
2014
Q1 | $1.85M | Buy |
+44,083
| New | +$1.85M | 0.23% | 124 |
|